Drug intelligence / Profile preview

BH1657

Development stage: Preclinical
Lead developer: Hanmi Pharmaceutical
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

BH1657 is a bispecific antibody being developed by Beijing Hanmei Pharmaceutical for the treatment of autoimmune diseases. It is designed to simultaneously target and neutralize two key pro-inflammatory cytokines: tumor necrosis factor-alpha (TNFα) and interleukin-17A (IL-17A). By inhibiting both pathways, BH1657 aims to provide enhanced therapeutic efficacy compared to monotherapies targeting either cytokine alone, potentially addressing a broader range of inflammatory signaling in conditions such as rheumatoid arthritis or psoriasis. The drug is currently in the IND-enabling stage of development.

Targets

IL-17A (Interleukin-17A)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on BH1657.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BH1657.

Explore the full profile